semaglutide 503b pharmacy FDA moves against compounding glp1's 503A Pharmacy | Compounded Medications

Under your doctors guidance, the dose increases in phases from 2 mg to 4 mg, 8 mg, and up to 12 mg per week

2022;97(4):E1625

What stands out: Enforcement focus on mass-marketing, not patient-specific compounding Clear limits on advertising claims, including prohibitions on calling compounded products generic, the same as, or clinically proven Reinforcement of FD&C Act authorities, including misbranding provisions and Section 503A requirements Shift as shortages resolve, removing the legal basis for broad compounding of GLP-1 drugs Expanded compliance tools, including warning letters, seizure, and injunction where violations persist Bottom line: This signals a firmer FDA posture as the GLP-1 market matures, reinforcing long-standing distinctions between FDA-approved drugs and unapproved compounded preparations, particularly when promoted directly to consumers at scale

It also has better outcomes than gastroparesis [31]